Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Agonist-Specific Conformations of the M2 Muscarinic Acetylcholine Receptor Assessed by Molecular Dynamics.

Randáková A, Nelic D, Doležal V, El-Fakahany EE, Boulos J, Jakubík J.

J Chem Inf Model. 2020 Mar 13. doi: 10.1021/acs.jcim.0c00041. [Epub ahead of print]

PMID:
32130001
2.

Novel M2 -selective, Gi -biased agonists of muscarinic acetylcholine receptors.

Randáková A, Nelic D, Ungerová D, Nwokoye P, Su Q, Doležal V, El-Fakahany EE, Boulos J, Jakubík J.

Br J Pharmacol. 2020 Jan 7. doi: 10.1111/bph.14970. [Epub ahead of print]

PMID:
31910288
3.

Analysis of equilibrium binding of an orthosteric tracer and two allosteric modulators.

Jakubík J, Randáková A, El-Fakahany EE, Doležal V.

PLoS One. 2019 Mar 27;14(3):e0214255. doi: 10.1371/journal.pone.0214255. eCollection 2019.

4.

Applications and limitations of fitting of the operational model to determine relative efficacies of agonists.

Jakubík J, Randáková A, Rudajev V, Zimčík P, El-Fakahany EE, Doležal V.

Sci Rep. 2019 Mar 15;9(1):4637. doi: 10.1038/s41598-019-40993-w.

5.

Novel long-acting antagonists of muscarinic ACh receptors.

Randáková A, Rudajev V, Doležal V, Boulos J, Jakubík J.

Br J Pharmacol. 2018 May;175(10):1731-1743. doi: 10.1111/bph.14187. Epub 2018 Apr 14.

6.

Role of membrane cholesterol in differential sensitivity of muscarinic receptor subtypes to persistently bound xanomeline.

Randáková A, Dolejší E, Rudajev V, Zimčík P, Doležal V, El-Fakahany EE, Jakubík J.

Neuropharmacology. 2018 May 1;133:129-144. doi: 10.1016/j.neuropharm.2018.01.027.

7.

Binding of N-methylscopolamine to the extracellular domain of muscarinic acetylcholine receptors.

Jakubík J, Randáková A, Zimčík P, El-Fakahany EE, Doležal V.

Sci Rep. 2017 Jan 16;7:40381. doi: 10.1038/srep40381.

8.

Secreted Isoform of Human Lynx1 (SLURP-2): Spatial Structure and Pharmacology of Interactions with Different Types of Acetylcholine Receptors.

Lyukmanova EN, Shulepko MA, Shenkarev ZO, Bychkov ML, Paramonov AS, Chugunov AO, Kulbatskii DS, Arvaniti M, Dolejsi E, Schaer T, Arseniev AS, Efremov RG, Thomsen MS, Dolezal V, Bertrand D, Dolgikh DA, Kirpichnikov MP.

Sci Rep. 2016 Aug 3;6:30698. doi: 10.1038/srep30698.

9.

Apolipoprotein E4 reduces evoked hippocampal acetylcholine release in adult mice.

Dolejší E, Liraz O, Rudajev V, Zimčík P, Doležal V, Michaelson DM.

J Neurochem. 2016 Feb;136(3):503-9. doi: 10.1111/jnc.13417. Epub 2015 Nov 19.

10.

Lipid-Based Diets Improve Muscarinic Neurotransmission in the Hippocampus of Transgenic APPswe/PS1dE9 Mice.

Janickova H, Rudajev V, Dolejsi E, Koivisto H, Jakubik J, Tanila H, El-Fakahany EE, Dolezal V.

Curr Alzheimer Res. 2015;12(10):923-31.

PMID:
26502816
11.

Towards predictive docking at aminergic G-protein coupled receptors.

Jakubík J, El-Fakahany EE, Doležal V.

J Mol Model. 2015 Nov;21(11):284. doi: 10.1007/s00894-015-2824-9. Epub 2015 Oct 9.

PMID:
26453085
12.

Structural Insight into Specificity of Interactions between Nonconventional Three-finger Weak Toxin from Naja kaouthia (WTX) and Muscarinic Acetylcholine Receptors.

Lyukmanova EN, Shenkarev ZO, Shulepko MA, Paramonov AS, Chugunov AO, Janickova H, Dolejsi E, Dolezal V, Utkin YN, Tsetlin VI, Arseniev AS, Efremov RG, Dolgikh DA, Kirpichnikov MP.

J Biol Chem. 2015 Sep 25;290(39):23616-30. doi: 10.1074/jbc.M115.656595. Epub 2015 Aug 4.

13.

Classical and atypical agonists activate M1 muscarinic acetylcholine receptors through common mechanisms.

Randáková A, Dolejší E, Rudajev V, Zimčík P, Doležal V, El-Fakahany EE, Jakubík J.

Pharmacol Res. 2015 Jul;97:27-39. doi: 10.1016/j.phrs.2015.04.002. Epub 2015 Apr 13.

14.

Molecular mechanisms of methoctramine binding and selectivity at muscarinic acetylcholine receptors.

Jakubík J, Zimčík P, Randáková A, Fuksová K, El-Fakahany EE, Doležal V.

Mol Pharmacol. 2014 Aug;86(2):180-92. doi: 10.1124/mol.114.093310. Epub 2014 May 28.

PMID:
24870405
15.

Changes in Membrane Cholesterol Differentially Influence Preferential and Non-preferential Signaling of the M1 and M3 Muscarinic Acetylcholine Receptors.

Michal P, El-Fakahany EE, Doležal V.

Neurochem Res. 2015 Oct;40(10):2068-77. doi: 10.1007/s11064-014-1325-z. Epub 2014 May 13.

16.

Outline of therapeutic interventions with muscarinic receptor-mediated transmission.

Jakubík J, Šantrůčková E, Randáková A, Janíčková H, Zimčík P, Rudajev V, Michal P, El-Fakahany EE, Doležal V.

Physiol Res. 2014;63 Suppl 1:S177-89. Review.

17.

Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors.

Šantrůčková E, Doležal V, El-Fakahany EE, Jakubík J.

PLoS One. 2014 Feb 18;9(2):e88910. doi: 10.1371/journal.pone.0088910. eCollection 2014.

18.

On homology modeling of the M₂ muscarinic acetylcholine receptor subtype.

Jakubík J, Randáková A, Doležal V.

J Comput Aided Mol Des. 2013 Jun;27(6):525-38. doi: 10.1007/s10822-013-9660-8. Epub 2013 Jun 28.

19.

Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid β(1-42).

Janíčková H, Rudajev V, Zimčík P, Jakubík J, Tanila H, El-Fakahany EE, Doležal V.

Neuropharmacology. 2013 Apr;67:272-83. doi: 10.1016/j.neuropharm.2012.11.014. Epub 2012 Nov 30.

20.

Characterization of the Drosophila adenosine receptor: the effect of adenosine analogs on cAMP signaling in Drosophila cells and their utility for in vivo experiments.

Kucerova L, Broz V, Fleischmannova J, Santruckova E, Sidorov R, Dolezal V, Zurovec M.

J Neurochem. 2012 May;121(3):383-95. doi: 10.1111/j.1471-4159.2012.07701.x. Epub 2012 Mar 14.

21.

A specific multi-nutrient formulation enhances M1 muscarinic acetylcholine receptor responses in vitro.

Savelkoul PJ, Janickova H, Kuipers AA, Hageman RJ, Kamphuis PJ, Dolezal V, Broersen LM.

J Neurochem. 2012 Feb;120(4):631-40. doi: 10.1111/j.1471-4159.2011.07616.x. Epub 2012 Jan 6.

22.

Subtype differences in pre-coupling of muscarinic acetylcholine receptors.

Jakubík J, Janíčková H, Randáková A, El-Fakahany EE, Doležal V.

PLoS One. 2011;6(11):e27732. doi: 10.1371/journal.pone.0027732. Epub 2011 Nov 16.

23.

NMR structure and action on nicotinic acetylcholine receptors of water-soluble domain of human LYNX1.

Lyukmanova EN, Shenkarev ZO, Shulepko MA, Mineev KS, D'Hoedt D, Kasheverov IE, Filkin SY, Krivolapova AP, Janickova H, Dolezal V, Dolgikh DA, Arseniev AS, Bertrand D, Tsetlin VI, Kirpichnikov MP.

J Biol Chem. 2011 Mar 25;286(12):10618-27. doi: 10.1074/jbc.M110.189100. Epub 2011 Jan 20.

24.

Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor.

Grant MK, Noetzel MJ, De Lorme KC, Jakubík J, Doležal V, El-Fakahany EE.

PLoS One. 2010 Dec 23;5(12):e15722. doi: 10.1371/journal.pone.0015722.

25.

Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy.

Jakubík J, Janíčková H, El-Fakahany EE, Doležal V.

Br J Pharmacol. 2011 Mar;162(5):1029-44. doi: 10.1111/j.1476-5381.2010.01081.x.

26.

Functional cholinergic damage develops with amyloid accumulation in young adult APPswe/PS1dE9 transgenic mice.

Machová E, Rudajev V, Smycková H, Koivisto H, Tanila H, Dolezal V.

Neurobiol Dis. 2010 Apr;38(1):27-35. doi: 10.1016/j.nbd.2009.12.023. Epub 2010 Jan 4.

PMID:
20053373
27.

Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors.

Jakubík J, Randáková A, El-Fakahany EE, Dolezal V.

BMC Pharmacol. 2009 Dec 28;9:15. doi: 10.1186/1471-2210-9-15.

28.

Weak toxin WTX from Naja kaouthia cobra venom interacts with both nicotinic and muscarinic acetylcholine receptors.

Mordvintsev DY, Polyak YL, Rodionov DI, Jakubik J, Dolezal V, Karlsson E, Tsetlin VI, Utkin YN.

FEBS J. 2009 Sep;276(18):5065-75. doi: 10.1111/j.1742-4658.2009.07203.x. Epub 2009 Aug 4.

29.

Detection of choline transporter-like 1 protein CTL1 in neuroblastoma x glioma cells and in the CNS, and its role in choline uptake.

Machová E, O'Regan S, Newcombe J, Meunier FM, Prentice J, Dove R, Lisá V, Dolezal V.

J Neurochem. 2009 Aug;110(4):1297-309. doi: 10.1111/j.1471-4159.2009.06218.x. Epub 2009 Jun 10.

30.

Membrane cholesterol content influences binding properties of muscarinic M2 receptors and differentially impacts activation of second messenger pathways.

Michal P, Rudajev V, El-Fakahany EE, Dolezal V.

Eur J Pharmacol. 2009 Mar 15;606(1-3):50-60. doi: 10.1016/j.ejphar.2009.01.028. Epub 2009 Jan 29.

31.

Importance and prospects for design of selective muscarinic agonists.

Jakubík J, Michal P, Machová E, Dolezal V.

Physiol Res. 2008;57 Suppl 3:S39-47. Epub 2008 May 13. Review.

32.

Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain.

Machová E, Jakubík J, El-Fakahany EE, Dolezal V.

J Pharmacol Exp Ther. 2007 Jul;322(1):316-23. Epub 2007 Apr 19.

PMID:
17446301
34.
35.

Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice.

Machová E, Jakubík J, Michal P, Oksman M, Iivonen H, Tanila H, Dolezal V.

Neurobiol Aging. 2008 Mar;29(3):368-78. Epub 2006 Nov 30.

PMID:
17140703
36.

Muscarinic M2 receptors directly activate Gq/11 and Gs G-proteins.

Michal P, El-Fakahany EE, Dolezal V.

J Pharmacol Exp Ther. 2007 Feb;320(2):607-14. Epub 2006 Oct 25.

PMID:
17065363
37.
38.

The transcriptional repressor REST is a critical regulator of the neurosecretory phenotype.

Bruce AW, Krejcí A, Ooi L, Deuchars J, Wood IC, Dolezal V, Buckley NJ.

J Neurochem. 2006 Sep;98(6):1828-40.

39.

Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors.

Jakubík J, El-Fakahany EE, Dolezal V.

Mol Pharmacol. 2006 Aug;70(2):656-66. Epub 2006 May 4.

PMID:
16675658
40.

Chronic treatment with amyloid beta(1-42) inhibits non-cholinergic high-affinity choline transport in NG108-15 cells through protein kinase C signaling.

Nováková J, Mikasová L, Machová E, Lisá V, Dolezal V.

Brain Res. 2005 Nov 16;1062(1-2):101-10. Epub 2005 Oct 26.

PMID:
16256077
41.
42.

Multiple promoters drive tissue-specific expression of the human M muscarinic acetylcholine receptor gene.

Krejci A, Bruce AW, Dolezal V, Tucek S, Buckley NJ.

J Neurochem. 2004 Oct;91(1):88-98.

43.

Regulation of signal transduction at M2 muscarinic receptor.

Krejcí A, Michal P, Jakubík J, Rícný J, Dolezal V.

Physiol Res. 2004;53 Suppl 1:S131-40. Review.

44.
45.

Beta-amyloid and cholinergic neurons.

Dolezal V, Kasparová J.

Neurochem Res. 2003 Apr;28(3-4):499-506. Review.

PMID:
12675138
46.

[Hyperbaric oxygen therapy in athletic injuries].

Dolezal V.

Cas Lek Cesk. 2002 May 24;141(10):304-6. Review. Czech.

PMID:
12078582
47.

[beta-Amyloid, cholinergic neurons and Alzheimer's disease].

Kasparová J, Dolezal V.

Cesk Fysiol. 2002 May;51(2):82-94. Review. Czech.

PMID:
12053492
48.

More than one way to toy with ChAT and VAChT.

Castell X, Diebler MF, Tomasi M, Bigari C, De Gois S, Berrard S, Mallet J, Israël M, Dolezal V.

J Physiol Paris. 2002 Jan-Mar;96(1-2):61-72.

PMID:
11755784
49.

Chronic exposure of NG108-15 cells to amyloid beta peptide (A beta(1-42)) abolishes calcium influx via N-type calcium channels.

Kasparová J, Lisá V, Tucek S, Dolezal V.

Neurochem Res. 2001 Sep;26(8-9):1079-84.

PMID:
11699934

Supplemental Content

Loading ...
Support Center